Research Paper Volume 15, Issue 13 pp 6503—6525
Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis
Figure 6. Schematic for Galectin-1-mediated AXL/MET signaling in sorafenib resistance in HCC cells. Galectin-1 was significantly overexpressed in Huh-7/SR cells and promoted MET and AXL phosphorylation, contributing to sorafenib resistance and decreased sorafenib-mediated ferroptosis. Combined treatment with sorafenib and the AXL/MET inhibitor blocked Galectin-1-mediated AXL/MET signaling, overcoming sorafenib resistance and sorafenib-mediated ferroptosis in Huh-7/SR cells.